IntroductionAspirin is widely used to relieve acute pain and reduce fever and inflammation. New 500 mg and 1000 mg aspirin rapid disintegrating tablets with small active ingredient particle size and sodium carbonate excipient were developed to replace regular 500 mg aspirin tablet formulation containing starch and cellulose. The rapid disintegrating aspirin tablets have been proven to show faster in-vitro dissolution and a shorter time to Cmax (Voelker 2012) resulting in faster pain relief (Cooper 2012). The current study correlates the site and time to complete tablet disintegration with the plasma concentration time profile, using γ-scintigraphy imaging technique. Two 400 mg ibuprofen tablet formulations (ibuprofen acid and ibuprofen lysine salt) have also been analyzed in this study. MethodsOpen label, randomized and four-way crossover trial in 12 healthy fasted males. Scintigraphy images and blood sampling were taken up to 4 h post dose. Tablets were radiolabelled with 4 MBq technetium (99mTc)-labelled DTPA using a drill and fill method (Wilson 2003). Site and time to complete tablet disintegration were derived from the scintigraphy images. Validated bioassays were used to measure plasma concentration. ResultsIn all subjects the aspirin formulations disintegrated rapidly and completely in the stomach (500 mg Aspirin: 9.0 min, 1000 mg Aspirin: 5.0 min). Complete disintegration of the ibuprofen tablets occurred in 5 and 4 out of 12 subjects in the small intestine. Time to complete disintegration was longer (acid: 37.5 min, lysine-salt: 37.5 min) than with the aspirin formulations. This correlates with pharmacokinetics: a substantial difference in Tmax between the two aspirin formulations (500 mg Aspirin: 20 min, 1000 mg Aspirin: 23 min) and the two ibuprofen formulations (acid: 68 min, lysine-salt: 42 min) was observed. ConclusionsThe gastrointestinal disintegration and systemic absorption of the aspirin formulations is faster compared to the ibuprofen formulations.
Read full abstract